{"id":45885,"date":"2026-07-27T22:00:00","date_gmt":"2026-07-27T20:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=1436f5cbde374642079f9dda7bbd3bfb"},"modified":"2026-07-27T22:00:00","modified_gmt":"2026-07-27T20:00:00","slug":"viiv-healthcares-2-drug-regimen-dovato-is-as-effective-as-3-drug-regimen-biktarvy-in-first-of-its-kind-head-to-head-study-in-treatment-naive-adults-living-with-hiv","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=45885","title":{"rendered":"ViiV Healthcare\u2019s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-na\u00efve adults living with HIV"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<b><i>Positive Week 48 data from the phase IIIb VOGUE study reinforce Dovato as an effective treatment option with fewer medicines than Biktarvy, across diverse populations<\/i><\/b><\/li>\n<li>\n<b><i>Findings build on 10 years of evidence supporting DTG\/3TC as the first and only oral 2-drug regimen for treatment-na\u00efve people living with HIV<\/i><\/b><\/li>\n<\/ul><p>LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced data to be presented this week at the 26<sup>th<\/sup> International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil, from the phase IIIb VOGUE study. Data show that <i>Dovato<\/i> (dolutegravir\/lamivudine (DTG\/3TC)) demonstrated non-inferior efficacy to <i>Biktarvy<\/i> (bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF)) in treatment-na\u00efve adults living with HIV, including people with high viral loads or a low CD4+ cell count.<sup>1<\/sup> The findings also reinforced DTG\/3TC\u2019s high barrier to resistance, with zero cases of treatment-emergent resistance identified across treatment arms.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260727256393\/en\/2857612\/4\/viiv%2Blogo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260727256393\/en\/2857612\/22\/viiv%2Blogo.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260727256393\/en\/2857612\/4\/viiv%2Blogo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260727256393\/en\/2857612\/21\/viiv%2Blogo.jpg\" \/><\/a><p>\n<b>Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said:<\/b> \"HIV treatment is lifelong, so the number of medicines people take over decades of care can matter. As the first randomised, head-to-head study comparing DTG\/3TC with BIC\/FTC\/TAF in treatment-na\u00efve adults living with HIV, VOGUE adds to 10 years of real-world evidence showing that people starting treatment can successfully manage their HIV with fewer daily drugs. The data demonstrate that from day one, we can potentially reduce the number of antiretroviral drugs a person receives with DTG\/3TC, without compromising on efficacy or the barrier to resistance.\u201d<\/p><p>\nThe ongoing multi-country, open-label, phase IIIb VOGUE study randomised 509 treatment-na\u00efve adults living with HIV-1 to receive either DTG\/3TC (n=254) or BIC\/FTC\/TAF (n=255), and treatment was initiated before the availability of baseline resistance testing results. At baseline, 47% of participants had a viral load \u2265100,000 copies\/mL, 16% had viral load \u2265500,000 copies\/mL and 16% had a CD4+ cell count &lt;200 cells\/mm<sup>3<\/sup>.<\/p><p>\nAt Week 48, virologic suppression (HIV-1 RNA &lt;50 copies\/mL) was achieved in 89% (n=226\/254) of participants receiving DTG\/3TC compared with 92% (n=235\/255) receiving BIC\/FTC\/TAF (adjusted difference: -3%, 95% confidence interval [-8%, 2%]), meeting the study\u2019s non-inferiority endpoint. Median time to viral suppression was rapid and similar in both groups (4.1 weeks). No treatment-emergent resistance was identified in either arm.<\/p><p>\nThe overall safety profiles for both treatment groups were comparable, with no new safety signals observed. A similar number of participants in each group (n=7 for DTG\/3TC; n=7 for BIC\/FTC\/TAF) stopped treatment due to not achieving or maintaining viral suppression.<\/p><p>\n<b>About <i>Dovato<\/i><\/b> <b>(dolutegravir and lamivudine)<\/b><\/p><p>\n<i>Dovato<\/i> is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg in the EU, and weighing at least 25 kg in the US, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.<\/p><p>\nPlease consult the full Summary of Product Characteristics for all the safety information: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fdocuments%2Fproduct-information%2Fdovato-epar-product-information_en.pdf&amp;esheet=54575103&amp;newsitemid=20260727256393&amp;lan=en-US&amp;anchor=Dovato+50+mg%2F300+mg+film-coated+tablets&amp;index=1&amp;md5=bc7eb677c4cb72d34d507a1ef7b3db52\" rel=\"nofollow\" shape=\"rect\"><i>Dovato<\/i> 50 mg\/300 mg film-coated tablets<\/a>.<\/p><p>\nTrademarks are owned by or licensed to the ViiV Healthcare group of companies.<\/p><p>\n<b>About ViiV Healthcare<\/b><\/p><p>\nViiV Healthcare is a global specialist HIV company established in November 2009 with GSK (LSE: GSK) and Shionogi as current shareholders. The company is dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. ViiV Healthcare\u2019s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.<\/p><p>\nFor more information on the company, its management, portfolio, pipeline, and commitment, please visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fviivhealthcare.com%2F&amp;esheet=54575103&amp;newsitemid=20260727256393&amp;lan=en-US&amp;anchor=viivhealthcare.com&amp;index=2&amp;md5=6794d5b86cc158b40d97d63ca083a6fe\" rel=\"nofollow\" shape=\"rect\">viivhealthcare.com<\/a>.<\/p><p>\n<b>About GSK<\/b><\/p><p>\nGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gsk.com%2Fen-gb%2F&amp;esheet=54575103&amp;newsitemid=20260727256393&amp;lan=en-US&amp;anchor=gsk.com&amp;index=3&amp;md5=4099d9f44939a0426995c738ba54c36b\" rel=\"nofollow\" shape=\"rect\">gsk.com<\/a>.<\/p><p>\n<b>Cautionary statement regarding forward-looking statements<\/b><\/p><p>\nGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the \u201cRisk Factors\u201d section in GSK\u2019s Annual Report on Form 20-F for 2025, and GSK\u2019s Q1 Results for 2026.<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Registered in England &amp; Wales:<\/b><\/p><\/td><td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">GSK plc<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nViiV Healthcare Limited<\/p><\/td><\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">No. 3888792<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nNo. 06876960<\/p><\/td><\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"\/>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><b>Registered Office:<\/b><\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">79 New Oxford Street<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nViiV Healthcare Limited<\/p><\/td><\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nLondon<\/p><\/td><td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nGSK Medicines Research Centre<\/p><\/td><\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">WC1A 1DG<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nGunnels Wood Road, Stevenage<\/p><\/td><\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"\/>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nUnited Kingdom<\/p><\/td><\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"\/>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nSG1 2NY<\/p><\/td><\/tr>\n<\/table><p>\n<b>References<\/b><\/p><p>\n<sup>1<\/sup> J. Ghosn et al. In VOGUE: DTG\/3TC 2-drug regimen is non-inferior to BIC\/FTC\/TAF 3-drug regimen in a randomized trial in adults with HIV naive to treatment. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>ViiV Healthcare enquiries:<\/b><br\/>Media:\n<br\/>Kate Senter\n<br\/>+44 (0) 77 9670 7446\n<br\/>(London)<\/p><p>\nMelinda Stubbee\n<br\/>+1 919 491 0831\n<br\/>(North Carolina)<\/p><p>\n<b>GSK enquiries:<\/b><br\/>Media:\n<br\/>Tim Foley\n<br\/>+44 (0) 20 8047 5502\n<br\/>(London)<\/p><p>\nSarah Clements\n<br\/>+44 (0) 20 8047 5502\n<br\/>(London)<\/p><p>\nKathleen Quinn\n<br\/>+1 202 603 5003\n<br\/>(Washington DC)<\/p><p>\nAlison Hunt\n<br\/>+1 540 742 3391\n<br\/>(Washington DC)<\/p><p>\nInvestor Relations:\n<br\/>Constantin Fest\n<br\/>+44 (0) 7831 826525\n<br\/>(London)<\/p><p>\nJames Dodwell\n<br\/>+44 (0) 20 8047 2406\n<br\/>(London)<\/p><p>\nMick Readey\n<br\/>+44 (0) 7990 339653\n<br\/>(London)<\/p><p>\nSteph Mountifield\n<br\/>+44 (0) 7796 707505\n<br\/>(London)<\/p><p>\nSam Piper\n<br\/>+44 (0) 7824 525779\n<br\/>(London)<\/p><p>\nJeff McLaughlin\n<br\/>+1 215 751 7002\n<br\/>(Philadelphia)<\/p><p>\nFrannie DeFranco\n<br\/>+1 215 751 3126\n<br\/>(Philadelphia)<\/p>","protected":false},"excerpt":{"rendered":"<p>Positive Week 48 data from the phase IIIb VOGUE study reinforce Dovato as an effective treatment option with fewer medicines than Biktarvy, across diverse populations<\/p>\n<p>Findings build on 10 years of evidence supporting DTG\/3TC as the first and only or&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-45885","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45885"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45885\/revisions"}],"predecessor-version":[{"id":45886,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45885\/revisions\/45886"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}